home / stock / alpmy / alpmy articles
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
- Open Innovation Hub Named SakuLabTM-Tsukuba will open at the Astellas Tsukuba Research Center - TOKYO and BOSTON, Oct. 10, 2023 /PRNewswire/ -- ...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc. ADR Company Name:
ALPMY Stock Symbol:
OTCMKTS Market:
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology PR Newswire - Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs tar...
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting PR Newswire XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurr...